Table 1 Baseline clinical characteristics of the cohort
From: Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma
mUC | mRCC | ||
|---|---|---|---|
Number of patients | 115 | Number of patients | 184 |
Biological sex, n (%) | Biological sex, n (%) | ||
Male | 96 (83.5) | Male | 143 (77.7) |
Female | 19 (16.5) | Female | 41 (22.3) |
Stage at initial diagnosis, n (%) | Stage at initial diagnosis, n (%) | ||
Localized NMIUC | 42 (36.5) | Localized RCC | 94 (51.1) |
Localized MIUC | 41 (35.7) | Metastatic RCC | 90 (48.9) |
Metastatic | 32 (27.8) | ||
Histology of the pathology specimen, n (%) | Histology of the pathology specimen, n (%) | ||
Pure urothelial | 99 (86.1) | Clear cell | 149 (81.0) |
Mixed urothelial and variant | 14 (12.2) | Papillary | 17 (9.2) |
Pure variant | 1 (0.9) | Chromophobe | 8 (4.3) |
Unknown | 1 (0.9) | Undifferentiated | 2 (1.1) |
Mixed | 1 (0.5) | ||
Unknown | 7 (3.8) | ||
Age at initial diagnosis, median (range) | 68.0 (23–86) | Age at initial diagnosis, median (range) | 62.0 (23–89) |
Age at metastatic diagnosis, median (range) | 71.0 (23–88) | Age at metastatic diagnosis, median (range) | 65.0 (26–89) |
Treatment history prior to baseline blood collection, n (%) | Treatment history prior to baseline blood collection, n (%) | ||
Cystectomy | 57 (49.6) | Nephrectomy | 129 (70.1) |
Bacillus Calmette-Guérin (BCG) | 31 (26.9) | ICI doublet | 13 (7.1) |
Platinum chemotherapy | 58 (50.4) | TKI monotherapy | 14 (7.6) |
Immunotherapy | 24 (20.9) | Combination ICI-TKI | 8 (4.3) |
Non-platinum chemotherapy (systemic) | 2 (1.7) | Other | 1 (0.5) |
Targeted therapy | 1 (0.9) | No systemic treatment or palliative | 148 (80.4) |
Antibody-drug conjugate | 1 (0.9) | Metastases n (%) | |
No systemic treatment or palliative | 29 (25.2) | Bone | 63 (34.2) |
Treatment line at time of baseline blood collection, n (%) | Lymph node | 102 (55.4) | |
First line | 64 (55.7) | Lung | 127 (69.0) |
Second line | 18 (15.7) | Liver | 30 (16.3) |
Third line | 4 (3.5) | Unknown | 7 (3.8) |
Maintenance | 4 (3.5) | Grade 3-4 irAEs n (%) | |
Palliative | 14 (12.2) | Present | 112 (69.6) |
Other | 12 (10.4) | Absent | 49 (30.4) |
Smoking history, n (%) | |||
Never smoker | 47 (40.9) | ||
Previous smoker | 58 (50.4) | ||
Current smoker | 10 (8.7) | ||
Follow up samples, (n) | |||
1 additional sample | 33 | ||
2 additional samples | 7 | ||
3 additional samples | 1 |
